港股異動 | 貝康醫療-B(2170.HK)漲超8% 券商指其為中國第三代試管嬰兒技術領航者
格隆匯7月13日丨貝康醫療-B(2170.HK)反彈8.15%,報21.9港元,總市值60億港元。中金首次覆蓋貝康醫療給予跑嬴行業評級,目標價28.64港元。該行稱貝康醫療擁有中國先進的輔助生殖平台,實現了包括植入前、產前和產後在內的全生殖週期覆蓋,為中國第三代試管嬰兒技術領航者。生殖遺傳學市場是新興的市場,具有較大潛力。此外,貝康的PGT-A產品是國內唯一獲藥監局批准的第三代IVF基因檢測試劑盒。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.